Cargando…

Feasibility of a twitter campaign to promote HPV vaccine uptake among racially/ethnically diverse young adult women living in public housing

BACKGROUND: Uptake and completion of the HPV vaccine is suboptimal. This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing. METHODS: We recruited a convenience...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, Jennifer D., Hollander, Justin, Gualtieri, Lisa, Alarcon Falconi, Tania M., Savir, Stephanie, Agénor, Madina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268465/
https://www.ncbi.nlm.nih.gov/pubmed/32487045
http://dx.doi.org/10.1186/s12889-020-08824-0
Descripción
Sumario:BACKGROUND: Uptake and completion of the HPV vaccine is suboptimal. This study assessed the feasibility of implementing a one-month Twitter campaign to promote knowledge about the human papillomavirus (HPV) vaccine among low-income women living in public housing. METHODS: We recruited a convenience sample (n = 35) of women ages 18–26 years residing in low-come, public housing in Massachusetts. We assessed the feasibility and acceptability of a communication campaign that consisted of daily Twitter messages. Online surveys assessed changes in HPV knowledge, attitudes, and vaccine intentions before and after the campaign. RESULTS: Most believed that Twitter was an acceptable educational strategy and remained engaged with the campaign throughout the intervention. We observed no changes in HPV knowledge, perceived benefits of or barriers to vaccination, decision self-efficacy, or vaccine intentions after the campaign, although perceived risk for cervical cancer decreased. CONCLUSIONS: Twitter may be a feasible and acceptable method for promoting knowledge about the HPV vaccine, but more research is needed to understand how best to reach low-income women with low levels of vaccine uptake. TRIAL REGISTRATION: Clinicaltrials.gov 1,603,045, retrospectively registered 0610/19.